Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 3, 2006. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on share repurchase activity.
- Shares Purchased: 500,000 ordinary shares of 25 pence each.
- Purchase Price: 1,403.01 pence per share.
- Purchase Date: November 3, 2006.
- Treasury Shares Held: 213,269,678 shares (post-purchase).
- Shares in Issue: 5,775,108,326 shares (excluding Treasury shares).
Material Changes
The material change reported is the reduction of outstanding shares through a buyback authorized by shareholders at the Annual General Meeting on May 17, 2006. The acquired shares are intended to be held in Treasury.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on operations, risks, contingencies, or unusual items. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities.
Investor Verification Points
- Verify the total cost of the 500,000 share repurchase based on the stated price of 1,403.01 pence.
- Confirm the updated total share count (5,775,108,326 in issue) against subsequent filings.
- Review the May 17, 2006 Annual General Meeting minutes to confirm the scope of the share buyback authority.